
Volunteers, friends vow to carry on work of late Chicago LGBTQ+ activist: ‘We're her legacy'
'If we have to do it with tears coming out our eyes, we gotta do it,' Foster, 57, said.
Tuesday marked Foster's first volunteer shift at GroceryLand, the long-running Edgewater food pantry for HIV-positive people, without the pantry's steadfast linchpin, Lori Cannon. A fixture of LGBTQ+ activism in Chicago and the driving force behind GroceryLand, Cannon died at home Aug. 3 of heart failure, a close friend told the Tribune. She was 74.
Less than 48 hours later, the doors of GroceryLand's 5543 N. Broadway brick-and-mortar stood open, as grieving volunteers returned to do what they had for years done side by side with Cannon: serve the community. They wouldn't have had it any other way, the volunteers said, as they vowed to carry on Cannon's legacy.
'This was her dream,' Foster said. 'This was her goal.'
Born in Ravenswood and raised in West Rogers Park, Cannon established what would ultimately become GroceryLand 37 years ago amid the AIDS epidemic of the 1980s.
Eleven years after AIDS was first reported in the United States, it was the leading cause of death for U.S. men ages 25 to 44. HIV disproportionally affects people in vulnerable populations that are often highly marginalized, stigmatized and criminalized, including the LGBTQ+ community, racial and ethnic minorities, women and girls, drug users and sex workers, according to the World Health Organization.
'I didn't understand what was happening,' Cannon told the Tribune in 2004 of the epidemic. 'But I knew I didn't like it. The horror, the heartbreak we experienced … and no one was paying attention.'
Cannon turned to organizing, becoming an early volunteer for Chicago House, which provides a range of services for people and families affected by HIV, and helped launch the city's local chapter of the national AIDS Coalition to Unleash Power, according to the Chicago LGBT Hall of Fame.
In 1988, Cannon co-founded Open Hand Chicago to deliver meals to people with AIDS. Six years later, Open Hand expanded to food pantries where clients could shop for their own free load of groceries, with the idea that they'd come away feeling more empowered in the process. GroceryLand was born.
Over time, the operation evolved, being renamed Vital Bridges in 2001 and 10 years later, becoming an arm of Heartland Alliance Health, whose parent organization split apart last year amid financial turmoil. In February, Heartland Alliance Health itself was on the brink of closure before receiving a multimillion-dollar donation that saved the organization from shutting down. Still, through it all, GroceryLand remained, with Cannon at the helm.
'Lori Cannon was a true ally in Illinois from her organizing days to founding Open Hand Chicago — she led the way with chutzpah and humor,' Gov. JB Pritzker wrote in a statement to social media recently.
That tenacity was palpable Tuesday, living on through the GroceryLand volunteers and clients Cannon leaves behind.
'We don't know what tomorrow's going to bring or how it's going to turn out,' Foster said as he wiped his eyes, his voice wavering.
Foster initially came to the organization as a client when it was still known as Open Hand, after he contracted HIV at 20 years old. From Florida, he fell in love with Chicago from the moment he saw 'two guys walking down the street holding hands … and it seemed normal to them,' he said.
Cannon gave Foster the 'guidance of the mother that I never had,' he said, sitting in GroceryLand's reception area as clients filtered in and out with canned goods, grains and vegetables in hand. All around, pride flags lined the pantry's walls while overhead, a doll resembling Cannon hung from angel wings, though the effigy had been part of the pantry's decor long before Cannon died as a standing homage to GroceryLand's 'guardian angel,' volunteers said.
'Will it be the same?' Foster said. 'Will we have the same support from the community? She knew so many people. She had so many connections. … Only time will tell. (But) the need is there.'
Chicago artist David Lee Csicsko said he'll be a part of GroceryLand 'until I'm gone.'
For more than 30 years, Csicsko has produced artwork for the pantry to liven the space and turn it into somewhere for not only 'nourishing your body but your mind and your soul and your heart,' he said. 'The constant thing was just making something that makes people smile.' That was important to Cannon, who exuded kindness and humor and knew every client that walked through the door by first name, Csicsko said.
Today, GroceryLand, with the help of some 30 volunteers, serves a few hundred regular clients, volunteer Maria Mavraganes said.
Mavraganes, 60, met Cannon when she was 16 years old, after she and her family, who had owned a restaurant in Lakeview for years, became involved in advocacy efforts early on in the AIDS epidemic, she said. When she retired four years ago, Mavraganes said she formally joined GroceryLand so she could volunteer 'for the community that gave so much to me and my family,' an opportunity she owed to Cannon.
'It's because of Lori and on Lori's behalf that we're all here.' she said.
When client Frank Frasier took a bad fall last year and tore a tendon in his leg, it was Cannon who kept in touch and ensured he'd still receive his groceries, he said. A friend introduced Frasier, a longtime survivor of HIV, to GroceryLand seven years ago, and he's been a client, as well as a part-time volunteer, since.
Cannon had this ability to 'make you feel like you're the most important person in the world,' said Frasier, who lived in Edgewater for 24 years but now lives in the suburbs. 'She never turned anybody away. Never. Whether it was a day's worth of food or a week's worth of food or whatever, even if they weren't a client, she didn't turn them away.'
Frasier said it was always Cannon's hope that someday, GroceryLand wouldn't be necessary anymore. He referenced a 2016 article by the former hyperlocal news website DNAinfo Chicago, in which Cannon was quoted as saying, 'I hope to hang up the shingle on my front door that says, 'We're going fishing, we're closing our doors, the need is not there, it's been a pleasure serving you all.''
Frasier said that dream still stands.
'I don't want (her legacy) to be a dusty plaque someplace. I want it to keep living and breathing. … We're her legacy. The people here,' he paused, choking up, 'are her legacy. Clients, the people working.'
Cannon's 'unwavering commitment to nourishing both bodies and spirits made Vital Bridges a lifeline for thousands,' Tamashiro continued, adding: 'We are profoundly grateful for (her) decades of leadership and love.'
Tamashiro said Heartland Alliance Health is 'taking time to thoughtfully consider next steps for GroceryLand, ensuring that any decisions reflect the care, community and values Lori brought to her work every day.'
Longtime Chicago performer Angelique Munro, who knew Cannon for 16 years, said the focus among Cannon's close network is 'the future of GroceryLand and the LGBTQ+ community' especially amid today's political climate.
Heartland Alliance Health, which relies on federal funding for an estimated 20% to 30% of its annual budget, has been closely monitoring 'proposed changes to federal funding with concern,' Tamashiro said, though he added that the organization is 'on strong financial footing' and 'well-positioned' to continue delivering care.
For the past 15 years, Munro, 55, has held an annual Thanksgiving food drive for GroceryLand to ensure that clients could take home a holiday meal. She plans to keep the tradition going this fall.
Cannon was like a mother to Munro, whose own mother died in 2006, she said. Losing Cannon has 'shattered' her, but 'we just have to continue on,' she said, 'because that's what she would want. … It's all about honoring her and keeping her memory alive.'
On that Tuesday afternoon, Derrick Fox walked towards GroceryLand with a black suitcase rolling behind him on the sidewalk. 'Are they servicing today?' the 63-year-old asked.
Fox, of Englewood, met Cannon when GroceryLand opened and is 'living witness to what (the pantry) has done for us by way of Lori,' he said.
'I'm a longtime survivor,' he said. 'And I'm a longtime survivor because of her.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Boehringer's Hernexeos receives fast-tracked FDA approval
Boehringer Ingelheim has received fast-track approval from the US Food and Drug Administration (FDA) for its targeted therapy, Hernexeos (zongertinib tablets), to treat non-small cell lung cancer (NSCLC). This approval succeeds the positive results of the Phase Ib Beamion-LUNG 1 trial (NCT04886804), with the oral tyrosine kinase inhibitor (TKI) demonstrating an objective response rate (ORR) of 75% in patients with HER2-positive NSCLC who had received prior lines of platinum-based chemotherapy. Its FDA approval makes it the first oral treatment for HER2-positive NSCLC. Hernexeos also triggered a duration of response (DOR) of more than six months in 58% of the 71 patients previously treated with chemotherapy alone, while 27% of the 34 individuals with prior exposure to chemotherapy and a HER2 targeted therapy experienced a DOR of this length. Impacting 2%-4% of patients diagnosed with NSCLC, HER2 mutations are associated with poor prognosis and a higher risk of brain metastasis, while treatment options are highly limited in this population. Due to Hernexeos' potential to fulfil unmet needs in this indication, the FDA granted Boehringer priority review and breakthrough therapy designation last year. The therapy's full approval will likely rely on verification of clinical benefit in a confirmatory trial. Dr John Heymach, co-ordinating investigator on the Beamion-LUNG 1 trial and chair of thoracic/head and neck medical oncology at the MD Anderson Cancer Centre, said: 'The approval of zongertinib offers an effective and targeted treatment option for patients with HER2-mutant NSCLC in the US that not only elicits a durable response, but also has a manageable safety profile. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' HER2-targeted therapy race heats up Though the current standard of care (SoC) for patients with HER2-mutated NSCLC still revolves around a platinum-based chemotherapy regimen, physicians are increasingly prescribing targeted therapies to improve outcomes. A notable example of this is AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), which became the first HER2-targeting therapy to receive approval for NSCLC in 2022. Following its accelerated FDA approval, the drug has already reached blockbuster status – raking in $4.1bn in 2024 for the company, according to Pharmaceutical Technology's parent company, GlobalData. GlobalData predicts that the drug is on track to pull in $14.6bn by 2031, highlighting the lucrative nature of the targeted oncology market. However, Hernexeos has demonstrated a higher ORR of 75% compared with Enhertu's 56% in the DESTINY-Lung02 trial. The TKI has also proved efficacious in patients who had previously received treatment with an ADC, suggesting that the TKI could absorb some of Enhertu's market share. Looking ahead, the drug may also face competition from other targeted therapies currently in Phase III clinical trials, with GlobalData giving Bayer's TKI sevabertinib a likelihood of approval (LoA) score of 81% in this indication. "Boehringer's Hernexeos receives fast-tracked FDA approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
6 hours ago
- Newsweek
Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump's former Surgeon General Jerome Adams has warned that "people are going to die" if the United States cuts funding for mRNA vaccine development. It comes after Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would terminate 22 Biomedical Advanced Research and Development Authority (BARDA) investments in mRNA vaccine development, representing nearly $500 million in federal funding. He said the decision was taken after reviews showed mRNA vaccines "failed protect effectively against upper respiratory infections like COVID and flu." Newsweek contacted the United States Department of Health and Human Services (HHS) for comment via email outside of regular working hours. Former Surgeon General Jerome Adams speaking at the White House in April 2020. Former Surgeon General Jerome Adams speaking at the White House in April 2020. AP Why It Matters Kennedy has been a longtime vaccine critic, and questioned their effectiveness on numerous occasions. His tenure as the head of HHS has seen top vaccine experts, food safety supervisors and other public-health officials either resign or be ousted. The 22 projects are led by major pharmaceutical companies, including Pfizer and Moderna, and aim to develop vaccines against the flu, COVID-19 and H5N1. mRNA technology, which underpins these vaccines, is widely credited with helping slow the spread of the coronavirus during the 2020 pandemic. Infectious-disease specialists have also warned that future pandemics will be harder to stop without the help of mRNA. What To Know Adams, who served in Trump's first administration, said in an interview with CBS News on Sunday that mRNA technology accelerated vaccine development by an estimated 18 to 24 months. He added that "by the most conservative estimates, at least 2 million lives were saved" during the pandemic because of mRNA vaccines. "It's a natural molecule that's in all of our bodies. It's like a recipe card that tells your body how to make a protein," he said. "And this new idea, again, helps us develop vaccines and new treatments for everything from cancer, melanoma - which my wife has - to HIV, to better flu vaccines." He added: "These are advances that are not going to happen now... people are going to die because we're cutting short funding for this technology." Several other infectious disease experts have also spoken out against Kennedy's decision. Rick Bright, the former director of BARDA, said on X: "A bad day for science, and huge blow to our national security. This decision will have dangerous repercussions." Dr. Thomas A. Russo, an expert in infectious diseases, told Newsweek that Kennedy's decision was "shortsighted," and said mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What People Are Saying RFK Jr. said on X last week: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." Infectious diseases expert Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, who specializes in pandemic preparedness, told Newsweek: "RFK's actions are completely devoid of value. They are only designed to serve more distrust of a proven and valuable vaccine technology. The repercussions of this decision will serve only to diminish the resiliency of the United States, and the world, to infectious disease threats." What Happens Next In his statement, Kennedy urged the department to shift from mRNA vaccines and "invest in better solutions," but did not specify alternatives. Lawmakers, public-health officials, and industry leaders are expected to press HHS for detailed timelines and alternative research investments options.


Medscape
7 hours ago
- Medscape
Four-Drug-Class-Resistant HIV Linked to Higher Death Risk
TOPLINE: Individuals with HIV who were resistant to all four antiretroviral drug classes experienced higher mortality than those who were not resistant, a difference primarily due to lower CD4 cell counts. METHODOLOGY: Researchers conducted a retrospective study to determine whether people living with HIV and resistance to four-drug classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors) faced a higher risk for death than those without such resistance. A total of 1097 patients with HIV were analysed, including 228 with four-drug class resistance (median age at baseline, 50 years; 72.4% men; median years of HIV diagnosis, 21.4 years) who were propensity score matched with 869 without such resistance, and followed up until a median of 8.67 years. The primary outcome was all-cause mortality. TAKEAWAY: During the follow-up period, 12.3% of patients with HIV and four-drug class resistance vs 7.7% of those without such resistance died (incidence rate ratio, 1.51; P = .063). When controlling for comorbidities, patients who were resistant to the four drug classes had a significantly higher risk for mortality than those who were not resistant (adjusted hazard ratio [AHR], 1.68; P = .024). In the four-drug-class-resistant group, lower CD4 cell counts had a significant indirect effect on mortality (AHR, 1.62; P < .001); however, the direct effect was not statistically significant. IN PRACTICE: "The priority for this vulnerable population is achieving virological control to enable immune recovery," the authors wrote. SOURCE: This study was led by Andrea Giacomelli, MD, Università degli Studi di Milano, Milan, Italy. It was published online on August 01, 2025, in Clinical Infectious Diseases. LIMITATIONS: This study was limited by its retrospective design and the small sample size of four-drug-class-resistant patients. Recruiting the control group from a single centre introduced selection and information bias. Moreover, approximately 30% of four-drug-class-resistant participants lacked data on causes of death. DISCLOSURES: This study was conducted as a part of routine work of the PRESTIGIO Registry, which received support from ViiV Healthcare, Gilead Sciences, Merck Sharp & Dohme, and Janssen-Cilag. Some authors reported receiving consultancy fees, speaker honoraria, and honoraria for lectures and presentations and having other ties with the registry funders and various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.